Amneal expects to meet or exceed FY2025 guidance; net leverage improves to 3.6x

Amneal Pharmaceuticals, Inc.

2025-FY EPS reported $0.22 revenue$3,018,760,000

Net revenue guidance $3.0B-$3.1B; Adj EBITDA $675M-$685M; Adj diluted EPS $0.75-$0.80.
Operating cash flow guided at $300M-$330M; capex ~$100M
Net leverage estimated at 3.6x as of Dec 31, 2025, down from 3.9x at Dec 31, 2024.
Company reaffirms guidance originally provided on Oct 30, 2025; expects to meet or exceed targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.